carditis; stem cell transplant For a variety of reasons, hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of developing bacterial, fungal, viral and other opportunistic infections. 1 Indwelling central venous catheters, the administration of immunosuppressive agents to allogeneic recipients and the disruption of skin and mucosal barriers by high-dose chemoradiotherapy and/or graft-versus-host disease (GVHD) all contribute to a predisposition to infection after HSCT. In addition, the development of GVHD can further delay the immunoreconstitution process which normally takes 6-12 months. 2, 3 Endocarditis has been reported infrequently in the setting of HSCT. A number of case reports and case series have described infectious endocarditis (IE) in HSCT patients [4] [5] [6] with the largest series involving seven patients. 7 Marantic or nonbacterial thrombotic endocarditis (NBTE) has also been documented in both individual reports 8, 9 and larger autopsy series. [10] [11] [12] Given the difficulty in making the diagnosis of endocarditis in the antemortem period and the low reported autopsy rate, it seems likely that the incidence of endocarditis is underestimated in HSCT patients.
This single institution review was undertaken to determine the incidence of endocarditis in a large cohort of patients that underwent HSCT. In addition, risk factors for its development, disease characteristics and outcome for affected patients was examined.
Patients and methods

Patient identification
A retrospective review of the computerized database and charts on 1547 patients who underwent HSCT in Vancouver between January 1986 and December 2001 was performed. Over this period, 793 patients underwent allogeneic HSCT (553 related-donor and 240 unrelateddonor), eight patients underwent syngeneic HSCT and 754 patients underwent autologous HSCT. Autopsy data were available on 162 patients, 48% of all patients who died of treatment-related causes.
Diagnosis of endocarditis
The diagnosis of infectious endocarditis was made based on the Duke Criteria described by Durack. 13 All patients had multiple positive blood cultures and a vegetation documented by echocardiogram or had autopsy evidence of an invasive fungal infection involving the endocardium. All cases of nonbacterial thrombotic endocarditis were identified at autopsy. In each case, the pathologic examination clearly documented typical thrombotic findings or revealed endocardial lesions with negative microbiologic testing.
Conditioning and supportive care
Patients received a variety of conditioning regimens although the vast majority received a high-dose busulfan (35% of patients) or a total body irradiation (TBI)-based regimen (45% of patients). Graft-versus-host disease (GVHD) chemoprophylaxis consisted primarily of cyclosporine and short-course methotrexate with or without other agents (73% of patients who received prophylaxis). Intestinal decontamination and/or antibacterial prophylaxis were not utilized. Beginning in 1992, antifungal prophylaxis was given to all patients and consisted of either oral or intravenous fluconazole or low-dose intravenous amphotericin B (10 mg/m 2 /day). In the event of a neutropenic or unexplained fever, broad-spectrum antibiotic cover typically consisted of an antipseudomonal beta-lactam agent and an aminoglycoside with or without vancomycin. Cytomegalovirus-negative blood products were given to all CMV-negative patients and ganciclovir was administered to allogeneic recipients taking steroids, or if weekly CMV antigenemia screens became positive. All HSV positive patients received prophylactic acyclovir beginning on day þ 1 and continuing until neutrophil engraftment. Patients were given sulfamethoxazole/trimethoprim or intravenous pentamidine as pneumocystis carinii prophylaxis until day þ 100, or until all immunosuppressive medications had been discontinued.
Results
Patient characteristics
In total, 20 cases of endocarditis were identified (1.3% of all patients) with baseline patient characteristics shown in Table 1 . A total of 11 patients underwent allogeneic HSCT and nine patients autologous HSCT. Only one patient had a pre-existing history of rheumatic fever and none of the patients had previously documented valvular heart disease. Of the 11 allogeneic recipients, 10 had previously developed acute GVHD; the remaining allogeneic patient experienced primary graft failure.
Clinical presentation
The most common clinical findings observed in the endocarditis patients were fever (60% of patients), dyspnea/pulmonary infiltrates (50% of patients) and a heart murmur (20% of patients). Three patients presented with congestive heart failure, two with septic shock and two patients with a primary neurological disorder (hemiplegia and headache with disorientation). One patient was noted to have fingernail splinter hemorrhages.
Microbiology
The majority of patients that developed endocarditis had demonstrable infection in blood, urine and/or bronchoalveolar lavage (BAL) specimens at some point following HSCT. A total of 12 patients had positive blood cultures (Staphylococcus aureus (three patients, one of whom also grew Enterococcus faecalis), S. epidermidis, Streptococcus viridans, Pseudomonas aeruginosa, Citrobacter freundii, Enterobacter agglomerans, Pseudoallescheria boydii, Candida albicans (two patients) and Candida pseudotropicalis). Six patients had a positive BAL (three cases of Aspergillus fumigatus and one case each of Candida albicans, Pneumocystis carinii and Cytomegalovirus), and one patient had a positive urine culture (Candida albicans). The latter patient had disseminated candidiasis involving the lungs, kidneys, heart and spleen on post-mortem examination. Based on culture results and the presence of vegetations on echocardiogram or at autopsy, a causative organism was established in 11 patients (Table 2 ). It should be noted that seven patients with autopsy findings that were most 
Autopsy results
Autopsy results were available on 16 of the endocarditis patients and in all but two patients, the diagnosis was not suspected prior to death. Thrombotic endocardial lesions were identified in eight patients, one post-allogeneic HSCT and seven post-autologous HSCT. Endocardial involvement with invasive Aspergillus was identified in four allograft recipients post-mortem and Candida endocarditis was identified in one allograft and two autograft patients at autopsy. There was a sterile vegetation identified in one allogeneic patient with primary graft failure. This patient had an underlying history of rheumatic fever, had mitral valve thickening and was being treated for Candida pneumonia.
Sites of involvement
Valvular lesions on the left side were most common with 10 patients having mitral valve involvement and six patients aortic valve involvement. Involvement of the tricuspid valve was observed in three patients and a pulmonic valve vegetation was also seen in three patients. Multivalvular disease was evident in five cases, including two patients who had vegetations on both the tricuspid and mitral valves. Multifocal nonvalvular endocardial lesions were noted in three patients, all due to disseminated Aspergillus infections. Papillary muscle involvement was noted in two cases with one patient having had a rupture of the papillary muscle. The site of involvement was different in the infectious endocarditis cases compared to the NBTE cases with right-sided involvement being present in four of nine cases of NBTE. A right-sided valvular lesion was identified in only one case of infectious endocarditis.
Patient outcome
Over the 16 year time period studied, transplant-related mortality for autologous, matched sibling and unrelateddonor stem cell transplant recipients was 11, 25 and 47%, respectively. The most common cause of TRM in allogeneic HSCT recipients was GVHD (60% of deaths) or hepatic/ pulmonary regimen-related toxicity (RRT) (20% of deaths). In the autologous HSCT setting, the majority of TRM was attributed to opportunistic infection (40% of deaths) or hepatic/pulmonary RRT (30% of deaths). Follow-up was available on all 20 patients with endocarditis with only one patient currently alive and well. This patient is 10 years after an aortic valve replacement for S. epidermidis endocarditis documented by blood culture and transthoracic echocardiogram 5 months post-unrelated donor HSCT. The other four patients who were diagnosed with endocarditis prior to death were not felt to be appropriate candidates for valve replacement surgery. Three of these patients subsequently died of cardiac decompensation and one patient died of overwhelming bacterial sepsis. Of the 15 patients diagnosed with endocarditis post-mortem, seven patients had died of adult respiratory distress syndrome, three patients of disseminated Aspergillus infection and two patients of relapsed malignancy. In addition, one patient died of CMV pneumonia, one from a fungal brain abscess and one from thrombotic thrombocytopenic purpura with multiple cerebral infarctions.
Discussion
Endocarditis is an infrequently described complication of HSCT. [4] [5] [6] [7] [8] [9] [10] [11] [12] Patients undergoing HSCT are at risk for the development of endocarditis for several reasons. In-dwelling central venous (Hickman) catheters are routinely utilized and may be left in place for several months. Myeloablative chemotherapy predictably results in neutropenia that lasts for weeks and full immunoreconstitution may take 12 months or longer. 3 Mucositis and GVHD may disrupt mucosal integrity further increasing the risk of septicemia.
IE is a well-known complication in patients with indwelling catheter-related sepsis, 14 and its true incidence in our study cohort was likely underestimated. The post-HSCT bacteremia rate for all 1547 patients in the current study was 30% and echocardiograms or autopsy results were only available in a small proportion of patients. Martino et al 7 have previously reported a preponderance of right-sided valvular lesions in HSCT recipients who developed IE and suggested that this implicated the central venous catheter itself as the source of the infection. However, our results showed that left-sided lesions are more common in IE and that multivalvular involvement was not infrequent. It should be kept in mind that a routine intestinal decontamination strategy was not utilized at our center. This may have reduced the relative incidence of right-sided cardiac lesions, as the gut is an alternative source of organisms and might be expected to affect the left-and right-sided chambers in a more equal fashion. In addition, NBTE, which represented almost one-half of the cases of endocarditis in our cohort, has previously been reported to affect the valves on the left side of the heart more commonly.
The vast majority of the allograft recipients who developed thrombotic or infectious endocarditis in our series (91% of patients) had prior evidence of acute GVHD. As previously noted, GVHD involving the gut or skin may compromise mucosal or skin integrity and thereby predispose to septicemia. It is also likely that the use of potent immunosuppressive agents to control the GVHD process in these patients further contributed to the development of infection.
Non-bacterial thrombotic endocarditis (NBTE) was documented in seven of 91 HSCT patients that underwent autopsy in one study. 10 The development of NBTE is also thought to be a multifactorial process. There is a wellrecognized association between NBTE and various malignancies and autoimmune disorders. 15 Typically, the underlying malignancy is a solid tumor with adenocarcinomas being the most common. 16 However, none of the endocarditis patients in our cohort had an autoimmune disorder, and only one patient underwent HSCT for a solid tumour (ovarian carcinoma).
Central venous catheter-related thrombosis is a frequent occurrence in HSCT recipients, 17 and these clots could conceivably extend to involve the endocardial surface resulting in an NBTE lesion. Catheter thrombosis was not noted in any of the 16 patients in our study in whom an autopsy was performed, nor was it documented on diagnostic imaging in any endocarditis patient prior to death. However, prothrombotic conditions such as hepatic veno-occlusive disease, disseminated intravascular coagulation or microangiopathic hemolysis may occur following HSCT. 18, 19 Procoagulant effects have also been ascribed to active GVHD. In a series of 27 patients with active acute GVHD, in whom no thrombotic events were identified, alterations in coagulation parameters included a significant rise in protein S, anti-thrombin III and tissue plasminogen activator levels along with a decrease in protein C levels. 20 Furthermore, acquired protein C deficiency has been described in patients who have developed NBTE. 9 Despite these laboratory findings, there was no increased incidence of GVHD in patients developing NBTE in the Patchell study. 10 Thrombotic cardiac findings have been noted at autopsy in patients who have previously received high-dose cyclophosphamide. 21 The use of total body irradiation may further potentiate this toxicity and both treatments are commonly used in tandem during HSCT conditioning. The stem cell infusion procedure itself should also be considered in the pathophysiology of NBTE. HSCT may result in the infusion of platelet and fibrin debris 22 that could contribute to thrombus formation although this material would be unlikely to pass beyond the pulmonary circulation.
Endocarditis is a rare but important complication seen in HSCT patients. The etiology of both infectious and NBTE is likely to be multifactorial in nature and acute GVHD and associated immunosuppression may increase the risk of IE in allogeneic recipients. IE is associated with a poor prognosis even with the use of aggressive antimicrobial therapy. The ante-mortem diagnosis of NBTE is rare and this condition may be more common than suggested by this retrospective review. Future efforts might focus on identifying risk factors for endocarditis following HSCT, which could allow for earlier diagnosis and more successful management strategies.
